V Annese

Summary

Country: Italy

Publications

  1. doi request reprint Emerging drug for diarrhea predominant irritable bowel syndrome
    Simona Deiana
    Emergency Department, Gastroenterology SOD2, AOU Careggi, Florence, Italy 39 55 7946035
    Expert Opin Emerg Drugs 20:247-61. 2015
  2. doi request reprint Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO
    Vito Annese
    Emergency Department, Gastroenterology Unit, AOU Careggi, Florence, Italy
    J Crohns Colitis 10:216-25. 2016
  3. doi request reprint Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease
    Vito Annese
    Department of Medical and Surgical Specialties, Gastroenterology, AOU University Hospital Careggi, Florence, Italy Electronic address
    Dig Liver Dis 46:963-8. 2014
  4. pmc PPARγ in Inflammatory Bowel Disease
    Vito Annese
    Gastroenterology Unit, Careggi, University Hospital, 50134 Florence, Italy
    PPAR Res 2012:620839. 2012
  5. ncbi request reprint Genetics and ulcerative colitis: what are the clinical implications?
    Anna Latiano
    IRCCS Casa Sollievo della Sofferenza, Laboratorio di Gastroenterologia, San Giovanni Rotondo, Italy
    Curr Drug Targets 12:1383-9. 2011

Collaborators

Detail Information

Publications5

  1. doi request reprint Emerging drug for diarrhea predominant irritable bowel syndrome
    Simona Deiana
    Emergency Department, Gastroenterology SOD2, AOU Careggi, Florence, Italy 39 55 7946035
    Expert Opin Emerg Drugs 20:247-61. 2015
    ..Therefore, development and validation of new therapies targeting at the molecular level are widely awaited...
  2. doi request reprint Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO
    Vito Annese
    Emergency Department, Gastroenterology Unit, AOU Careggi, Florence, Italy
    J Crohns Colitis 10:216-25. 2016
    ..Finally, the majority of studies reported in the literature do not reveal any increase in mortality with immunosuppressant therapy or biologicals/anti-TNF agents. ..
  3. doi request reprint Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease
    Vito Annese
    Department of Medical and Surgical Specialties, Gastroenterology, AOU University Hospital Careggi, Florence, Italy Electronic address
    Dig Liver Dis 46:963-8. 2014
    ....
  4. pmc PPARγ in Inflammatory Bowel Disease
    Vito Annese
    Gastroenterology Unit, Careggi, University Hospital, 50134 Florence, Italy
    PPAR Res 2012:620839. 2012
    ..This paper will specifically focus on potential role of PPARγ in the predisposition and physiopathology of IBD and will analyze its possible role in medical therapy...
  5. ncbi request reprint Genetics and ulcerative colitis: what are the clinical implications?
    Anna Latiano
    IRCCS Casa Sollievo della Sofferenza, Laboratorio di Gastroenterologia, San Giovanni Rotondo, Italy
    Curr Drug Targets 12:1383-9. 2011
    ....